Coding mutations of the CDKN2A gene on chromosome 9p21 cosegregate with 25-60% of familial melanoma cases, but there remains a number of 9p21-linked kindreds that lack germline coding mutations of CDKN2A. We sequenced CDKN2A exons 1a, 2, 3, and the adjacent intronic regions in 167 melanoma-prone families (at least two affected first-degree relatives), and detected four splice site variations, three of which cosegregate with the disease. RT-PCR experiments verified that these three variants, including an AGgt to ATgt mutation that demonstrates a founder effect, do affect splicing. While an exon 1a splice donor site mutation incompletely abolishes splicing, the correctly spliced mRNA yields a protein (Q50P) that cannot effectively interact with CDK4. We also performed RT-PCR on mRNA from 16 melanoma-prone kindreds to search for cryptic splice sites deep within introns, but identified no splice variants. Meanwhile, we screened 139 affected families using allelespecific PCR for the recently discovered IVS2À105A4G mutation, but found only one family that possesses this alteration. We conclude that splice site mutations do predispose to disease in a subset of melanoma-prone kindreds. Characterization of additional splice site variants and other noncoding alterations of CDKN2A should allow us to detect a wider range of mutations in atrisk patients.
Introduction
Cutaneous malignant melanoma (MIM #155601) comprises about 1% of all cancer cases in European populations, but its mortality rate is over 2%, due to the propensity of this tumor to metastasize. In 8-12% of all cases, there is a family history of the disease; and in 50-80% of melanoma-prone kindreds, the disease segregates as an autosomal dominant trait linked to the MLM2 locus on chromosome 9p21. In addition, affected members or obligate carriers may also develop pancreatic cancer, albeit at a lower frequency than melanoma.
The tumor suppressor gene CDKN2A (encoding p16
INK4a
) is allelic to MLM2, and germline coding mutations in exons 1a and 2 of CDKN2A cosegregate with melanoma in a subset of 9p21-linked families. The molecular lesions that predispose to melanoma in 'mutation-negative' 9p21-linked kindreds are unknown. We and others have sequenced the nearby CDKN2B gene (encoding p15 INK4B ), but have observed no germline mutations of this candidate gene in melanoma-bearing individuals (Liu et al., 1997) . Mutations of exon 1b, which encodes the alternate reading frame protein p14 ARF , do occur in cases of melanoma, but such alterations are very rare (Rizos et al., 2001; Hewitt et al., 2002) . We have speculated that mutations in the noncoding regions of CDKN2A may be underestimated by current screening protocols. In support of this notion, we have described a G-34T transversion in the 5 0 untranslated region (5 0 UTR) of this gene that generates an aberrant AUG initiation codon. The mutation segregates with melanoma, and probably arose from a common founder in the United Kingdom .
We hypothesized that some noncoding mutations affect splicing of the p16
INK4a transcript, thereby yielding gene products with reduced or absent CDK4-inhibitory function. In support of this hypothesis, Petronzelli et al. (2001) reported a germline G to C transversion at the splice acceptor of intron 1 (IVS1À1G4C) that segregates with affected cases in a melanoma/neurofibroma kindred. The resultant mis-spliced transcripts for p16 INK4a and p14 ARF both lacked exon 2. In addition, Harland et al. (2001) described an intronic mutation (IVS2À105A4G) that creates a false splice donor site, resulting in nonfunctional splice variants. In this paper, we report additional germline CDKN2A splice site mutations that alter p16
INK4a transcripts in a subset of melanoma-prone families. Specifically, by sequencing exons and the adjacent intronic regions, we found four splice site variations. RT-PCR and sequencing demonstrate that three of these affect splicing. In addition, we used RT-PCR and sequencing to search for differentially spliced products that result from cryptic splice sites deep within introns.
Results

Splice site mutations in consensus regions
Germline coding mutations of CDKN2A represent only a subset of melanoma-prone families that are linked to 9p21. To address the possibility that individuals with mutations that affect splicing comprise a portion of these apparently CDKN2A mutation-negative families, we sequenced 20-100 bp of intronic sequences adjacent to the 5 0 and 3 0 regions of exons 1a and 2 to detect alterations in the splice donor and acceptor. We found four variations that can potentially affect the splicing of the p16
INK4A mRNA (Table 1) . They include, respectively, an exon 1 splice donor mutation (AGgt to CGgt (c. 149A4C)), an intron 1 splice acceptor polymorphism (tggcagGT to tgccagGT (IVS1À4G4C)); and two alterations that affect the exon 2 splice donor (AGgt to AGtt (IVS2 þ 1G4T) and AGgt to ATgt (c. 457G4T)]. While the phenotypes and pedigrees for some of the families bearing the mutations have been described (Table 1 and references therein), we now present the molecular analyses. RT-PCR shows that the intron 1 polymorphism does not affect splicing of the message, and we will not discuss it further here.
Exon 2 mutations disrupt normal splicing
To verify that each variation alters splicing, we carried out RT-PCR on mRNA from the corresponding lymphoblastoid cell lines. Since the intron þ 1 G at the eukaryotic splice donor site is 100% conserved (Shapiro and Senapathy, 1987) , we expected the AGgt to AGtt (IVS2 þ 1G4T) variant to eliminate splicing activity at that site. Indeed, RT-PCR of RNA extracted from immortalized lymphoblastoid cells derived from the heterozygote mutation carrier yielded two products: one wild-type sized and another smaller mis-spliced species (Figure 1a) . Interestingly, while the exon 2 G (G457) is conserved in only 78% of donor sites (Shapiro and Senapathy, 1987) , the AGgt to ATgt (c. 457G4T) mutation demonstrated a pattern of mis-splicing that was identical to its AGtt counterpart described above ( Figure 1a) . We sequenced the cDNA in each case and determined that the aberrant RT-PCR products arise from the splicing of a cryptic donor site located within exon 2 to the wild-type acceptor site of exon 3 (Table 1 ; Figure 1b ), thus splicing out 74 bp encoded by exon 2. The predicted protein products of both exon 2 donor splice mutants thus lack 24 amino acids encoded by exon 2 and possess a frame shift in exon 3 that yields six amino acids followed by a termination codon. The resultant protein lacks two of the four ankyrin repeats and -based on the structural analyses of p16
INK4a and its relatives (Luh et al., 1997; Byeon et al., 1998; Li et al., 1999) -will not bind CDK4. A second laboratory has confirmed the mis-splicing of the IVS2 þ1 mutant (AGtt; Rutter et al., Oncogene, in press ).
Genotypes of families with the exon 2 ATgt mutation
Among the patient samples that we analysed, individuals from two families bear the exon 2 ATgt mutation. This scenario may arise in two ways: (1) the mutation originated in one individual many generations ago, and apparently unrelated families bearing this mutation are in fact descended from this original founder, or (2) the alteration occurred at a mutation hotspot in CDKN2A in multiple founders.
To address these possibilities, we determined whether a common haplotype is shared by mutation carriers in the two families. We used polymorphic microsatellite markers to type the CDKN2A genomic region (Figure 2a) , and found that all mutation carriers share a common haplotype (Figure 2b ) across eight adjacent markers spanning 2.7 Mb. Even in the case of Family 3679, where we could not determine the segregating allele for a specific microsatellite marker, the individuals still demonstrate a genotype consistent with the common haplotype. We conclude that the two families arose from a common founder bearing the ATgt mutation. Currently, we are unable to determine whether the family mentioned by Moskaluk et al. (1998) also arose from the same founder, and whether the families described by Hussussian et al. (1994) and MacKie et al. (1998) share a common haplotype with the FF family described here.
Exon 1 mutation disrupts either splicing or p16
INK4a function
The exon 1 mutation A149C (AGgt to CGgt) alters an A residue that is only 58% conserved among donor splice consensus sequences (Shapiro and Senapathy, 1987) . We carried out RT-PCR of RNA extracted from the corresponding lymphoblastoid cells and detected two distinct products ( Figure 3a ). We first sequenced the aberrantly sized band, and observed an abnormal cDNA in which a cryptic exon 1 splice donor G81 (immediately following codon 27) is spliced to the (Figure 3b ). The mis-spliced mRNA lacks 69 bp encoded by exon 1, and the predicted protein suffers an in-frame deletion of 23 amino acids, which constitute part of ankyrin repeats 1 and 2. Since the ankyrin repeats are essential for the interaction between p16
INK4A and CDK4, the mutant protein will not function as a cell cycle transition inhibitor (Byeon et al., 1998) .
We then sequenced the normally migrating RT-PCR product and observed two cDNA species that represent transcripts from either the wild-type (A149) or the mutant (C149) allele. We conclude that the mRNA in the heterozygous lymphoblastoid cells comprises three transcripts. The A149 allele expresses wild-type mRNA, while its mutant counterpart expresses two species of message: (1) correctly spliced mRNA that predicts a missense, highly nonconservative mutation, glutamine to proline (Q50P); and (2) an aberrantly spliced mRNA that predicts a truncated and nonfunctional p16 INK4A . The level of the aberrantly spliced mRNA species appears to be slightly higher than that of its correctly spliced counterpart, based on the intensity of the upper and lower RT-PCR bands (Figure 3a) . To address this observation in a more quantitative fashion, we cloned the upper and lower PCR products into the TA cloning vector (Invitrogen) and observed 54 vs 47 recombinant bacterial colonies, respectively. Therefore, the ratio of upper to lower cDNA is approximately equal.
To determine the expression ratio of the wild-type vs missense mRNAs (both comprise the upper band), we took advantage of the fact that the A to C mutation abolishes a BstNI restriction site. cDNA from the mutant C allele yields a 300 bp band upon digestion, in place of the 178 and 122 bp bands from the wild-type A allele. A total of 50 inserts were not digested by the enzyme, whereas four inserts were. Assuming a binomial distribution of wild-type (W) and mutant (M) upper and lower strands post-PCR, then the distribution of W to M is:
Since the M homozygote and the WM heterozygote dsDNA is not cut with BstNI, then W 2 ¼ 4, and 2WM þ M 2 ¼ 50. We calculate that the ratio of M to W (i.e. the C to A allelic ratio) is 5.3 : 2 (i.e. the steady-state level of the mutant mRNA is B2.5 times that of its wild-type counterpart in the lymphoblastoid cell line). We were unable to obtain peripheral blood lymphocytes to determine whether the proportions among wild type, mutant (correctly spliced), and mutant (mis-spliced) are similar in vivo.
Yeast two-hybrid analysis of the Q50P mutant protein Although a portion of the mRNA representing the AGgt to CGgt mutant allele is spliced correctly, the A-C transversion does predict a highly nonconservative codon change of glutamine to proline (Q50P). To examine the function of the mutant p16
INK4A , we performed a yeast two-hybrid assay to compare the relative interaction of the Q50P mutant and its wild-type counterpart with CDK4. We used a mutant p16 INK4A that lacks two amino acids (L104 and D105) as a negative control, since this protein has a greatly reduced level of binding activity compared to wild type at both 30 and 371C. We fused the corresponding cDNAs to the activation domain of VP16, and the wild-type CDK4 to the DNA-binding domain of the lexA bacterial transcription factor, which specifically binds sequences within the lexA binding site upstream of the bgalactosidase gene. Interaction between functional p16
INK4a and CDK4 results in the expression of the bgalactosidase reporter, whose enzymatic activity we quantitated in a colorimetric assay. This assay will detect temperature-sensitive mutation if performed on yeast grown both at 301C and at 371C; many missense variants of p16 INK4A do exhibit this behavior Ruas and Peters, 1998) . For each temperature, we normalize the wild-type protein as having 100% binding activity. As predicted (see Discussion), the Q50P mutant was temperature-sensitive and bound poorly to its target: we observed 8.37% of binding activity at 301C, and only 1.37% at 371C (Figure 4) .
RT-PCR screen for splice site mutations
Direct sequencing of exons and adjacent sequences will not detect deep intronic mutations that affect splicing. To identify novel transcripts resulting from aberrant splicing events due to such alterations, we extracted RNA from EBV-transformed lymphoblastoid cells of 18 cases derived from 16 melanoma-prone families, 15 of which lacked germline coding or splice site mutations of CDKN2A. As control, we used RNA from lymphoblastoid cells from a member of the 16 th family. This patient bears a 19-bp deletion in exon 2, which results in a novel Proper splicing still occurs at the regular donor site, but still leads to an amino-acid change from glutamine to proline; and aberrant splicing occurs immediately after codon 27 mRNA 19 bases shorter than its wild-type counterpart (Gruis et al., 1995) . We performed first-strand synthesis using a specific primer to sequences in the 3 0 UTR (5 0 end at 176 bp after the stop codon) and amplified the cDNA by PCR using primers PCR1-f and PCR1-r (Table 2) . We amplified an aliquot of the first PCR with nested primers PCR2-fa and PCR2-r (Table 2 ) and analysed the products by agarose gel electrophoresis. We did not observe differentially sized alleles, as might be expected from aberrant splicing. Since agarose gels do not resolve DNA species with slight differences in length, we also sequenced each RT-PCR product to search for ambiguous sequences that arose from mis-splicing events. We found that all RT-PCR products represented wild-type cDNA species (data not shown).
Screening of the IVS2À105A4G mutation
Recently, Harland et al. (2001) reported an intronic mutation of CDKN2A in six English melanoma pedigrees (IVS2À105A4G) that creates a novel splice donor site 105 bases 5 0 of exon 3. Using allele-specific PCR, we screened 139 melanoma-prone families (ascertained up to September 2001) that lack known melanoma-associated mutations. We found only one family that bears the variant, and conclude that the prevalence of this mutation in the multiethnic Toronto population is less than its prevalence in the UK population sampled by Harland et al. (2001) .
Discussion
The role of CDKN2A germline mutations in melanoma has been investigated by many groups worldwide. In the majority of cases, the frequency of germline coding mutations observed in the coding regions of the CDKN2A gene is less than expected, given the frequency of melanoma families linked to chromosome 9p21. In addition, the frequency and specific mutation type of CDKN2A alterations vary enormously in different populations . We have hypothesized that such differences in CDKN2A mutation detection might be explained either by (1) noncoding mutations of the gene, as explored in this study; or (2) by the effect of other melanoma susceptibility genes . The discoveries of melanoma-predisposing mutations in the 5 0 UTR and in the introns (Harland et al., 2001; Petronzelli et al., 2001 ) of CDKN2A support this hypothesis.
To address the possibility that aberrant splicing of the p16
INK4a message might be associated with melanoma susceptibility, we screened patients from families that lacked germline CDKN2A mutations by a combination of two methods: first, we sequenced genomic DNA to detect mutations of the wild-type splice donor, acceptor, or branch point sites that directly alter normal splicing events. The three mutations (AGtt, ATgt, and CGgt) that affect splicing belong to this category. Second, we searched for deep intronic mutations that might create novel splice donor or acceptor sites. The discovery of the intronic mutation by Harland et al. (2001) demonstrated that mutations that create a novel splice site can indeed occur. We did not detect such mis-splicing events by RT-PCR analysis of p16 INK4A lymphoblastoid mRNA. However, we cannot exclude the possibility that some intronic mutations might elude detection by RT-PCR by splicing to novel 3 0 sequences that are unrecognized by our current oligonucleotide primers.
Individuals in the two families that bear the exon 2 ATgt mutation share a common haplotype, indicating proteins to CDK4 is normalized to the wild-type p16 INK4a . The binding activities of a negative control (6 bp del) and the Q50P mutant are measured this mutation arose in a founder common to both kindreds. Founder effects occur in many CDKN2A mutations, including: G101W (Ciotti et al., 2000) , an exon 2 19-bp deletion (Gruis et al., 1995) , 113 ins R (Hashemi et al., 2001) , M53I (Pollock et al., 1998) , G-34T and V126D (Goldstein et al., 2001) . Most of these mutations occur within specific geographical locations and/or ethnic groups. Of note, we detected the À105 intronic splice donor mutation in only one of 139 (0.7%) melanoma families that lack coding mutation of CDKN2A. In contrast, Harland et al. (2001) described this alteration in six of 84 (7%) coding mutation-negative UK families. This discrepancy in mutation detection frequency of one order of magnitude highlights the importance of defining the population(s) in which CDKN2A analysis is to be performed. To date, only one CDKN2A variant (the N-terminal 24-bp duplication) is an exception to this rule, as it arises in a mutation hotspot. Specifically, haplotype analyses at this locus have demonstrated at least five independent founders (Pollock et al., 1998 and our lab data) . This region of CDKN2A is probably inherently unstable due to mitotic recombination between two imperfect 24-bp repeats naturally present in the wild-type sequence (Pollock et al., 1998) . It is essential to analyse mRNA products from cell lines or tissues in order to understand the functional consequences of a potential splice site mutation. For instance, Hussussian et al. (1994) previously predicted that the mis-splicing event stemming from the AGgt to AGtt mutation would lead to codon changes from DIPD* (exon 3) to GED* (intron 2), due to readthrough past the exon 2 donor splice site. In fact, an RT-PCR assay using message from AGgt/AGtt heterozygous lymphoblastoid cells demonstrated a cryptic splice donor site arising in exon 2, the use of which could not have been predicted prior to our analysis. Characterization of additional splice site mutations revealed that the same cryptic site was used in the exon 2 donor mutation AGgt to ATgt.
There has been considerable debate as to whether germline mutations of CDKN2A are solely responsible for melanoma susceptibility, or whether mutations in exon 2 that also affect the predicted sequence of p14 ARF play a role in tumorigenesis. Quelle et al. (1997) introduced six missense mutations into the shared sequences of p16 INK4A and p14 ARF . Of these, two caused the complete loss of p16 INK4A function, but none affected p14 ARF . While exon 1b, which encodes protein sequences unique to p14 ARF , is necessary and sufficient for G1 arrest in vitro, it is not clear that a similar G1 arrest will occur in vivo (Rizos et al., 2001) . However, many mutations of exon 2 affect p16 INK4A sequence and function alone, and leave p14 ARF unchanged (Quelle et al., 1997) . In keeping with these observations, the exon 2 cryptic splice donor site that we describe in this paper is located downstream of the p14 ARF termination codon.
Although mRNA from the AGgt to CGgt mutant allele can be spliced correctly, the resultant mRNA predicts a highly nonconservative codon change of glutamine to proline (Q50P). We predicted that this alteration would adversely affect protein function for the following reasons: first, p16
INK4A contains four helixturn-helix structures known as ankyrin motifs, the second and third of which contribute most of the interactions between p16
INK4a and CDK4/6 (Byeon et al., 1998) . Q50 is part of a one-turn helix that constitutes the first portion of the second motif, and this residue stabilizes the organization of the second ankyrin repeat and its adjacent neighbors. In addition, Q50 is a component of a polar pocket that binds CDK4 (Byeon et al., 1998) . Taken together, there is little doubt that function of the Q50P variant will be compromised. To confirm this hypothesis, we performed a yeast twohybrid assay to compare the relative interaction of the Q50P mutant and its wild-type counterpart with CDK4. As predicted, the mutant p16
INK4A interacted poorly with its target.
In summary, we have demonstrated that splice site mutations in the CDKN2A gene contribute to melanoma predisposition. Taken together with previously described mutations in the 5 0 UTR and both introns, these data demonstrate that noncoding mutations of this gene play a significant role in melanoma susceptibility.
Materials and methods
DNA, RNA, and cell lines
The population in our study comprises of 167 American and Canadian melanoma-prone kindreds, defined as families with at least two affected first-degree relatives, who have no known melanoma-associated mutations. Following informed consent (The Sunnybrook and Women's College Health Sciences Centre, Toronto, ON, Canada), we drew blood from affected members of melanoma-prone kindreds, prepared DNA and RNA (Liu et al., 1995) , and transformed the lymphocytes with Epstein-Barr Virus (EBV) as previously described (Coligan et al., 1999) . We expanded the immortalized cell lines in RPMI-1640 media with 15% heat-inactivated fetal bovine serum (561C for 30-45 min), 2 mm l-glutamine, and 10 mg/ml gentamycin (all GIBCO BRL, MD, USA) until they reached a density of 8 Â 10 5 cells/ml.
Germline CDKN2A sequencing
For all 167 samples, we sequenced exons 1a and 2 of the CDKN2A gene as described in Liu et al. (1999) . In addition, we amplified exon 3 using the primers E3PCR-f and E3PCR-r and sequenced the products using the same primers (Table 2) .
Confirmation and detection of splice site mutations with RT-PCR of the CDKN2A mRNA
We annealed 10 pmol of the reverse transcription primer (RT; Table 2 ) to 3 mg of total RNA at 701C, and carried out firststrand cDNA synthesis using Superscript II Reverse Transcriptase (GIBCO BRL) at 421C. After treatment with RNase H (MBI Fermentas, ON, Canada), we amplified the cDNA using primers PCR1-f and PCR1-r, and further amplified these products with the nested primers PCR2-fa and PCR2-r (Table 2 ). Both PCR reactions used the Taq polymerase (GIBCO BRL) with standard buffer conditions, 5% DMSO, 1.6 mm MgCl 2 , and 0.2 mm dNTP. The PCR products were analysed on 1.5% agarose gels and purified using the Concertt Rapid Gel Extraction Purification System (GIBCO BRL).
Sequencing of RT-PCR products
We sequenced the RT-PCR products (30 ng) on both strands using the primers PCR2-fa and PCR2-r (Table 2) . We carried out the reaction using the dRhodamine Terminator Ready Reaction Mix (ABI PRISM Dye Terminator Kit, PerkinElmer, CA, USA) and the accompanying protocol, and analysed the reaction mixtures using the ABI PRISM310 Genetic Analyzer (Perkin-Elmer).
Genotype analysis for the exon 2 ATgt mutation
To determine whether the occurrence of the ATgt mutation in the two families (Table 1) is a result of a founder effect, we performed genotype analysis on the DNA of the affected individuals who bear the variant. The microsatellite markers used in the analysis were D9S1749, D9S916, D9S7369, D9S974, D9S942, D9S1748, D9S1604, and D9S171 ( Figure 2a ). We obtained primer sequences for all markers (except D9S7369) from the Genome Database (http:// www.gdb.org/), and designed primers for marker D9S7369:
and reverse 5 0 -GGACTCCTCTCTAACTTATTC-3 0 . We labeled all forward primers with one of 5-FAM, HEX, or TET (Integrated DNA Technologies, IA, USA), and typed each marker using standard PCR conditions (above) at an annealing temperature of 31C for 35 cycles. We then ran aliquots of the PCR products on the MJ Basestation (MJ Research, CA, USA), and scored the sizes of the alleles using the computer program Cartographer v1.2.6sg (MJ Bioworks, WI, USA).
Quantitation of splice variants of the AGgt-CGgt mutation
We extracted total RNA from the lymphoblastoid cell line bearing the AGgt-CGgt mutation at the exon 1 donor site, and performed RT and first PCR as described above. Then we further amplified the cDNA with nested primers PCR2-fb and PCR2-r (Table 2) , and analysed the products on 1.5% agarose gels. Finally, we ligated the products into the TA cloning vector and transformed Top10F 0 cells using the Original TA Cloning s Kit (Invitrogen, CA, USA). We picked colonies bearing insertions, diluted each in 10 ml of sterile water, and screened 1 ml of the diluted bacteria with PCR using primers PCR2-fb and PCR2-r. We analysed the PCR products on 1.5% agarose gels, and purified the wildtype-sized band PCR products using the Concertt Rapid Gel Extraction Purification System. We digested the purified PCR product with BstNI (New England Biolabs, ON, USA), and analysed the products on 1.5% agarose gels. The C allele yields a 300 bp band upon digestion, in place of the 178 and 122 bp bands from the wild-type A allele.
Yeast two-hybrid assay
Using PCR-based mutagenesis techniques, we engineered the Q50P mutation into a pVP16 vector (gift from S Hollenberg, Fred Hutchinson Cancer Research Center, Seattle) that already contained the full-length cDNA of CDKN2A. We substituted the wild-type CDKN2A cDNA in the original vector with one that contained the Q50P mutation, and performed a colorimetric yeast two-hybrid assay as previously described in Monzon et al. (1998) to assess the interaction between the Q50P mutant and CDK4.
Allele-specific PCR for the IVS2À105A4G mutation
We sampled at least one affected individual from 139 different melanoma families (ascertained up to September 2001) who had previously tested negative for coding p16 mutations. These 'melanoma families' have at least two members with the disease, and were ascertained between March 1996 and December 2000 through the Familial Melanoma Clinic at the Toronto-Sunnybrook Regional Cancer Centre. Using the primers WT-F, Mut-F, and p16-3R (Harland et al., 2001) and control primers cdk6-F and cdk6-R (Shennan et al., 2000) , we screened these families for the IVS2À105A4G mutation (Harland et al., 2001) . The PCR reactions, modified from Harland et al. (2001) , used the Taq polymerase (GIBCO BRL) with standard buffer conditions, 1.5 mm MgCl 2 and 0.2 mm dNTP. We employed the following amplification conditions: 961C -1 min; five cycles of (961C -25 s, 701C -45 s, and 721C -45 s); 21 cycles of (961C -25 s, 651C -50 s, and 721C -45 s); 4 cycles of (961C -25 s, 551C -1 min, and 721C -2 min); and 721C -7 min. The PCR products were analysed on 1.5% agarose gels.
